于本公告日期，Yili Investment持有公司合共4亿股股份，占公司已发行股份(不包括库存股份)约 72.62%。根据公司可得资料及就董事所知及所信，倘股权增持计划实施，公司仍将维持已发行股份的 足够公众持股量。公司董事会认为，Yili Investment的股权增持计划显示控股股东对集团前景的长期承 诺及坚定信心。 格隆汇9月29日丨卡罗特(02549.HK)公告，董事会接获公司控股股东Yili Investment Holdings Ltd通知， 基于对公司价值的认可和对公司未来整体业务发展及增长潜力的信心，Yili Investment计划自本公告日 期起计6个月内增持公司股权，金额不低于2000万港元。 ...

Core Viewpoint - China Bank has strategically increased its stake in Zhongyin Consumer Finance to 47.98% through the acquisition of shares from existing shareholders, aiming to enhance corporate governance and comply with regulatory requirements [1] Group 1: Shareholding Changes - The China Banking and Insurance Regulatory Commission approved China Bank's acquisition of 3.558% of Zhongyin Consumer Finance from Shenzhen Bode Innovation Investment Co., Ltd. and 1.617% from Beijing Sequoia Shengyuan Management Consulting Co., Ltd. [1] - Following this transaction, China Bank's direct ownership in Zhongyin Consumer Finance has risen to 47.98% [1] - Additionally, China Bank holds an indirect stake of 13.23% in Zhongyin Consumer Finance through Zhongyin Credit Card (International) Co., Ltd. [1] Group 2: Corporate Governance and Compliance - The approval notice emphasizes that Zhongyin Consumer Finance must adhere to relevant laws and regulations during the shareholding change process [1] - The company is required to strengthen its equity management, optimize its shareholding structure, and strictly control related party transactions [1] - There is a focus on improving corporate governance and internal control mechanisms to mitigate and resolve risks [1]

Group 1 - President Trump has demanded major pharmaceutical companies to take measures to lower drug prices in the U.S. within 60 days, threatening to use "all means" if they refuse [1] - This action highlights the U.S. government's strong intervention in drug pricing, increasing uncertainty regarding future profitability for pharmaceutical companies [1] - Investors are concerned about the potential compression of profit margins for drug companies, which may lead to sustained pressure on stock prices in the short term [1] Group 2 - Genscript Biotech announced a strategic increase in its stake in I-Mab, investing $30.9 million, making it the largest shareholder with approximately 16.1% ownership [2] - This investment is expected to enhance Genscript's competitiveness in the innovative drug sector and provide financial support to I-Mab for accelerating its clinical pipeline development [2] - The partnership is anticipated to have positive implications for shareholders of both companies [2] Group 3 - Anhui Province has initiated a centralized procurement process for monoclonal antibody biological agents, with a focus on 8 specific monoclonal antibodies, including a competitive landscape for Bevacizumab with 13 manufacturers [3] - The centralized procurement is likely to compress profit margins for pharmaceutical companies but may also accelerate market consolidation and encourage companies to improve R&D efficiency and cost control [3] - Short-term stock prices for related pharmaceutical companies may face pressure, while long-term benefits could arise from increased industry concentration and the development of innovative drugs [3] Group 4 - Borui Pharmaceutical has signed a cooperation and research agreement with China Resources Sanjiu for the development, registration, production, and commercialization of BGM0504 injection in mainland China [4] - The agreement includes milestone payments from China Resources Sanjiu totaling up to 282 million yuan, which will aid in advancing the commercialization process of BGM0504 [4] - This collaboration is expected to facilitate the rapid transformation of Borui's innovative achievements into marketable products, positively impacting the company's future operating performance [4]

Group 1 - Jiangsu Yunsong Capital Management Co., Ltd. increased its stake in Shenzhen Expressway (Deep Expressway) to 10% by acquiring 10.81 million H-shares between April 15 and May 27, 2025, at prices ranging from HKD 6.41 to HKD 6.73 per share [1][2] - The funding for this acquisition was sourced from legal self-owned and self-raised funds, indicating a strong financial backing for the investment [1] - Yunsong Capital previously subscribed to 243 million A-shares of Shenzhen Expressway at a price of RMB 13.17 per share, investing nearly RMB 3.2 billion [1][2] Group 2 - Yunsong Capital plans to further increase its holdings in Shenzhen Expressway H-shares within the next 12 months, depending on market conditions [3] - The company was established in 2015 with a registered capital of RMB 13.7 billion and is a wholly-owned subsidiary of Jiangsu Communications Holding Co., Ltd., which operates several expressway companies [3] - Shenzhen Expressway completed a private placement in March 2025, raising RMB 4.7 billion, with a significant portion allocated to the Shenzhen Outer Ring Expressway project, which has a total investment of RMB 29.4 billion [6]

Transaction Overview - The company plans to acquire a total of 21,034,313 non-listed shares of Fuhong Hanlin at a price of HKD 24.60 per share, representing approximately 3.87% of the total shares outstanding as of the announcement date [2][7] - The total transaction value amounts to HKD 517,444,099.80, which is equivalent to approximately RMB [2][7] - Following the completion of this acquisition, the company's ownership in Fuhong Hanlin will increase from 59.56% to 63.43% [3][9] Related Party Transactions - The acquisition includes a related party transaction as the company’s executive director, Ms. Guan Xiaohui, is also a director of Wuxi Tongshan, which is a related party [3][9] - The shares acquired from Wuxi Tongshan amount to 4,666,667, constituting part of the related party transaction [3][9] Regulatory Compliance - The acquisition does not constitute a major asset restructuring as defined by the relevant regulations [4][10] - No approval from the board of directors or shareholders is required for this transaction [5][11] Company Background - Fuhong Hanlin, established in February 2010 and listed on the Hong Kong Stock Exchange in September 2019, focuses on the research, production, and sales of monoclonal antibody drugs [12] - As of the announcement date, Fuhong Hanlin has a total of 543,494,853 shares, including 163,428,541 H-shares and 380,066,312 non-listed shares [12] Financial Performance - As of December 31, 2024, Fuhong Hanlin reported total assets of RMB 1,059,752,000, equity attributable to shareholders of RMB 301,362,000, and total liabilities of RMB 758,390,000 [13] - For the year 2024, Fuhong Hanlin achieved revenue of RMB 572,445,000 and a net profit of RMB 82,047,000 [13] Seller Information - Wuxi Tongshan, one of the sellers, was established in May 2016 and has total assets of RMB 9,519,000 as of December 31, 2024 [14] - Other sellers include Shanghai Shanwu, Zhoushan Guoyun, and Henlink, each with varying business focuses and financial standings [15][16][17] Impact on the Company - The acquisition reflects the company's confidence in Fuhong Hanlin's growth and value, enhancing its stake in a key antibody technology platform [19]